135 related articles for article (PubMed ID: 20849384)
1. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia.
Miyawaki S; Hatsumi N; Tamaki T; Naoe T; Ozawa K; Kitamura K; Karasuno T; Mitani K; Kodera Y; Yamagami T; Koga D
Leuk Lymphoma; 2010 Oct; 51(10):1855-61. PubMed ID: 20849384
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
3. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
4. WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia.
Sakamoto Y; Mariya Y; Sasaki S; Teshiromori R; Oshikiri T; Segawa M; Ogura K; Akagi T; Kubo K; Kaimori M; Funato T
Tohoku J Exp Med; 2009 Oct; 219(2):169-76. PubMed ID: 19776535
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
6. Detectable Wilms' tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution's experience.
Yamauchi T; Negoro E; Lee S; Takai M; Matsuda Y; Takagi K; Kishi S; Tai K; Hosono N; Tasaki T; Ikegaya S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Anticancer Res; 2013 Aug; 33(8):3335-40. PubMed ID: 23898100
[TBL] [Abstract][Full Text] [Related]
7. WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors.
Ujj Z; Buglyó G; Udvardy M; Beyer D; Vargha G; Biró S; Rejtő L
Pathol Oncol Res; 2016 Jan; 22(1):217-21. PubMed ID: 26531831
[TBL] [Abstract][Full Text] [Related]
8. The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.
Ido K; Nakamae M; Koh H; Okamura H; Nanno S; Nishimoto M; Takeoka Y; Hirose A; Nakashima Y; Hashimoto Y; Nakane T; Hino M; Nakamae H
Transplantation; 2019 Oct; 103(10):2201-2210. PubMed ID: 30801534
[TBL] [Abstract][Full Text] [Related]
9. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
[TBL] [Abstract][Full Text] [Related]
10. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
[TBL] [Abstract][Full Text] [Related]
11. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
12. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
[TBL] [Abstract][Full Text] [Related]
13. Assessment of WT1 Expression as a Marker of Treatment Outcome in Karyotype Normal Acute Myeloid Leukemia Patients in Pakistan.
Ahmed ZA; Shaikh MS; Moatter T
J Coll Physicians Surg Pak; 2016 May; 26(5):441-2. PubMed ID: 27225156
[TBL] [Abstract][Full Text] [Related]
14. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.
Gaiger A; Schmid D; Heinze G; Linnerth B; Greinix H; Kalhs P; Tisljar K; Priglinger S; Laczika K; Mitterbauer M; Novak M; Mitterbauer G; Mannhalter C; Haas OA; Lechner K; Jäger U
Leukemia; 1998 Dec; 12(12):1886-94. PubMed ID: 9844919
[TBL] [Abstract][Full Text] [Related]
15. Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission.
Asgarian Omran H; Shabani M; Vossough P; Sharifian R; Tabrizi M; Khoshnoodi J; Jeddi-Tehrani M; Rabbani H; Shokri F
Leuk Lymphoma; 2008 Feb; 49(2):281-90. PubMed ID: 18231915
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and Prognostic Impact of Wilms' Tumor 1 (WT1) Gene, Including SNP rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (CN-AML): An Iranian Experience.
Toogeh G; Ramzi M; Faranoush M; Amirizadeh N; Haghpanah S; Moghadam M; Cohan N
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):e21-6. PubMed ID: 26725263
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients.
Mossallam GI; Abdel Hamid TM; Mahmoud HK
Hematology; 2013 Mar; 18(2):69-73. PubMed ID: 23394625
[TBL] [Abstract][Full Text] [Related]
18. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
19. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy.
Sato H; Kobayashi T; Kameoka Y; Teshima K; Watanabe A; Yamada M; Yamashita T; Noguchi S; Michisita Y; Fujishima N; Kuroki J; Takahashi N
Int J Clin Oncol; 2024 Apr; 29(4):481-492. PubMed ID: 38334897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
